Consider Nebius (NBIS) for its explosive growth potential, backed by an $18 billion Microsoft contract and a valuation that is seen as extremely cheap for the AI infrastructure space. Hims & Hers (HIMS) is presented as a high-conviction buy around $37, with accelerating 47% revenue growth and a valuation described as "dirt cheap" for a profitable company. For a catalyst-driven swing trade, Oscar Health (OSCR) offers significant upside to the $30s if government healthcare subsidies are extended. As a deep value play, CoreMedics (CRMD) is considered "way too cheap" given its 96% gross margin and extremely low valuation multiples. Lastly, The Real Brokerage (REAX) is rapidly gaining market share with 50% growth, positioning it for major gains when the real estate market eventually recovers.

Hims & Hers (HIMS)

• The speaker describes HIMS as the "future of healthcare" and a "data-driven, big tech company in the making" that could potentially take over healthcare in the US.
• The company is expanding beyond its well-known products (like for ED) and is now attacking verticals like primary care with a labs offering.
• Despite losing a partnership with Novo for branded GLP-1 drugs, the company reported a strong Q3, beating expectations and even its own Q1 results when it still had the partnership.
• It has an active $250 million share buyback program and is cash flow positive.
• Key Metrics Mentioned:
  • Revenue Growth: 47%, which the speaker notes is an acceleration compared to two years ago.
  • Valuation (EV/GP/RG): 0.11, which is described as "dirt cheap."
  • Rule of 40: The company achieves a "Rule of 60," exceeding the benchmark by 50%.

Takeaways

• The speaker is extremely bullish, stating they "cannot believe this stock is this cheap" at a price of $37.
• The investment thesis is based on the company being significantly undervalued relative to its high growth rate, profitability, and expansion into new, large healthcare markets.
• The strong performance after losing a major partnership is seen as a sign of the underlying business's resilience and strength. The speaker believes the stock should have risen 30% after its Q3 report.

CoreMedics (CRMD)

• CRMD is a health tech company focused on providing anti-infection and antimicrobial products.
• Its key product is a hemodialysis solution that prevents infections for dialysis patients, which is noted to save significant money for Medicare.
• The company recently acquired Melinta, another firm of similar size, to diversify its product portfolio in the anti-infection space.
• The stock price recently "dumped" despite a good quarter, which the speaker attributes to broader market liquidity issues affecting many growth stocks.
• Key Metrics Mentioned:
  • Valuation (EV/GP/RG): 0.029, described as the cheapest among over 30 similar companies the speaker tracks.
  • Gross Margin: An "insane" 96%.
  • Forward EV/Adjusted EBITDA: 8x.
  • Forward EV/Gross Profit: 1.59x.

Takeaways

• The speaker is bullish due to the extreme valuation gap, calling the stock "way too cheap."
• This is presented as a deep value opportunity in the health tech sector. The company's high gross margins and extremely low valuation multiples suggest the market may be mispricing the stock, especially after the recent sell-off.

Nebius (NBIS)

• NBIS is positioned as a potential new "GPU hyperscaler" with a key differentiator: a proprietary AI software stack similar to what AWS offers, which goes beyond just providing hardware.
• The management team consists of former founders and leaders from Yandex (the "Google of Russia") who left after the conflict in Ukraine.
• The company has secured massive contracts, including an $18 billion deal with Microsoft and a roughly $3 billion deal with Meta.
• Key Metrics Mentioned:
  • Revenue Growth: Projected to grow 1600% (a 10-20x increase) over the next 12 months.
  • Valuation (EV/GP/RG): 0.04, which the speaker calls "among the cheapest I've ever seen" and suggests the stock is 30 times cheaper than the market.

Takeaways

• The speaker is exceptionally bullish, stating the initial stock price reaction to $135 after the Microsoft deal was the "correct reaction" before it sold off with the rest of the AI sector.
• The investment thesis is centered on explosive, contract-backed revenue growth and a unique competitive advantage through its software stack.
• The current low valuation is seen as a massive disconnect from the company's fundamental prospects, making it a potentially huge opportunity in the AI infrastructure space.

Oscar Health (OSCR)

• OSCR is a health insurance company operating in the Affordable Care Act (ACA) marketplace. The speaker views it as more of a "swing trade" for a 3-5 year hold rather than a 10+ year investment.
• The company has stated it does not need an extension of the ACA subsidies to meet its growth targets.
• Key Metrics Mentioned:
  • Valuation (EV/GP/RG): 0.024, which is described as "absolutely crazy" cheap.

Takeaways

• The speaker is bullish on the valuation but cautious about the industry.
• There is a clear potential catalyst: if the ACA subsidies are extended, the speaker notes that "a lot of people are expecting this stock to bounce back to the 30s."
• This is presented as a value play with a specific, near-term political catalyst. The primary risk mentioned is the politically-driven nature of the health insurance industry. Even at $16, it is considered "still too cheap."

The Real Brokerage (REAX)

• REAX is a real estate brokerage that is growing rapidly despite what the speaker calls the "most awful real estate market."
• Its business model is designed to attract the top 20% of high-performing realtors by offering attractive commission incentives after they hit certain transaction targets. This allows REAX to gain market share from competitors.
• The speaker prefers it to other real estate tech companies like Opendoor (OPEN).
• Key Metrics Mentioned:
  • Revenue Growth: Growing at a 50% clip, with growth numbers comparable to high-flyers like HIMS and SOFI.
  • Valuation (EV/GP/RG): 0.08.
  • Rule of 40: 53.

Takeaways

• The speaker is very bullish, highlighting the company's ability to grow market share in a downturn.
• This is an under-the-radar growth stock in a beaten-down sector. The investment thesis is that by attracting top agents now, REAX is positioning itself for massive upside when the real estate market eventually recovers.
• The speaker suggests a potential market turn could happen after a new, more "dovish" Fed chair is appointed, possibly in May 2026.

Zeta Global (ZETA)

• ZETA is an "AI native" marketing software company that could be a threat to incumbents like Salesforce (CRM).
• It uses a "top-down" sales approach, targeting large enterprise customers (Fortune 1000), similar to Palantir (PLTR).
• Its software integrates various marketing functions into a single, non-technical platform.
• Key Metrics Mentioned:
  • Forward Revenue Growth: Almost 30%.
  • Valuation (EV/GP/RG): 0.19. While higher than the other stocks mentioned, the speaker notes this is extremely cheap for its sector (SaaS IT software), where peers trade at an average of 0.8. This makes ZETA roughly four times cheaper than its peer group.
  • Rule of 40: 49.
  • Dollar-Based Net Retention: 119-120%.

Takeaways

• The speaker is bullish, calling the stock "very interesting at this level."
• This is a "growth at a reasonable price" (GARP) opportunity. The company is considered significantly undervalued compared to its software peers, despite having strong growth, high net retention, and a product that is clearly resonating with large customers.
• The recent sell-off is seen as a buying opportunity caused by macro liquidity issues, not company-specific problems.